Lung cancer is the most common cause of cancer death in both men and women. Eighty percent of all newly diagnosed lung cancers are non-small cell lung cancers (NSCLC), and over 75 percent present with advanced stage disease. For this reason as well as the predilection for distant recurrence after complete resection, most patients are treated with chemotherapy alone or in combination with other modalities. Unfortunately, the majority of NSCLC are chemoresistant despite treatment regimens with second or third generation of chemotherapeutic agents. Tumor chemoresistance has been attributed to the ability of cells to overcome programmed cell death (apoptosis). Recently, it has been established that chemotherapy upregulates the NF-kappaB transcription factor and this is associated with cellular resistance to chemotherapy-induced apoptosis. With this understanding, experiments were performed to determine whether NF-kappaB provided a similar cell survival signal in NSCLC cell lines following the addition of gemcitabine and cisplatin, two genotoxic agents commonly used to treat NSCLC. Preliminary data demonstrates that these chemotherapeutic agent induce NF-kappaB transcriptional activity. More importantly, the loss of NF- kappaB sensitizes NSCLC cell lines to chemotherapy-induced apoptosis. Although cell death induced by chemotherapy involves death receptor pathways in certain cell types, chemotherapy- induced apoptosis in NSCLC cells did not involve either Fas- or caspase-8-dependent death receptor pathways. In contrast, NF- kappaB was required to overcome mitochondrial-mediated apoptosis following chemotherapy addition. In addition, ceramide has recently been shown to inhibit the anti-apoptotic P13K/Akt pathway as well as activate NFkappaB. Since the loss of NF- kappaB activity sensitizes NSCLC cells to chemotherapy-induced apoptosis, the major goal of this proposal is to examine the cell signaling mechanisms governing apoptosis and chemoresistance following the addition of chemotherapy. To achieve this objective, we will use established (by the P.I.) cell lines which lack NF-kappaB activity and compare them to controls. These cells will be exposed to chemotherapeutic agents and apoptotic and anti-apoptotic signaling pathways will be examined in vitro.
The specific aims of the proposal are to: 1) establish whether chemotherapy kills NSCLC cells through mitochondrial-dependent mechanisms, 2) determine whether the redox status of the cell is responsible for modulating NF-kappaB-dependent cell survival in response to chemotherapy, and 3) determine the role of ceramide as both a pro- and anti-apoptotic mediator following chemotherapy. These studies will provide important insight into how chemotherapy activates apoptotic pathways, as well as mechanisms by which tumors become chemoresistant through upregulation of NF-kappaB. The ultimate goal of this study is to provide the necessary background for the initiation of novel treatment strategies designed to treat patients with advanced lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA083920-03
Application #
6522517
Study Section
Subcommittee G - Education (NCI)
Program Officer
Eckstein, David J
Project Start
2000-08-05
Project End
2005-07-31
Budget Start
2002-08-01
Budget End
2003-01-31
Support Year
3
Fiscal Year
2002
Total Cost
$66,623
Indirect Cost
Name
University of Virginia
Department
Surgery
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Liu, Yuan; Denlinger, Chadrick E; Rundall, Brian K et al. (2006) Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem 281:31359-68
Rundall, Brian K; Denlinger, Chadrick E; Jones, David R (2005) Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 138:360-7
Denlinger, Chadrick E; Rundall, Brian K; Jones, David R (2005) Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. J Thorac Cardiovasc Surg 130:1422-9
Denlinger, Chadrick E; Rundall, Brian K; Keller, Michael D et al. (2004) Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 78:1207-14; discussion 1207-14
Denlinger, Chadrick E; Keller, Michael D; Mayo, Marty W et al. (2004) Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 127:1078-86
Denlinger, Chadrick E; Rundall, Brian K; Jones, David R (2004) Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128:740-8
Mayo, Marty W; Denlinger, Chadrick E; Broad, Robert M et al. (2003) Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem 278:18980-9
Jones, David R; Broad, R Michael; Comeau, Laurey D et al. (2002) Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation. J Thorac Cardiovasc Surg 123:310-7
Mayo, Marty W; Madrid, Lee V; Westerheide, Sandy D et al. (2002) PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 277:11116-25